Nephrotic syndrome on sickle cell disease: the impact of Hydroxyurea

被引:0
|
作者
Cunha, Margarida [1 ]
Simao, Carla [1 ]
Ferrao, Anabela [1 ]
Palare, Maria Joao [1 ]
机构
[1] Hosp Santa Maria, Pediat, Lisbon, Portugal
关键词
sickle cell disease; nephrotic syndrome; paediatrics; haematology (drugs and medicines); CHILDREN;
D O I
10.1136/bcr-2020-237545
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nephropathy is a common under-recognised complication of sickle cell disease (SCD) and one of the main factors of poor prognosis in these patients. The association between nephrotic syndrome and SCD in children is rare. Strategies for sickle cell nephropathy prevention are still poorly established. Blood pressure control as well as monitoring of microalbuminuria and renal function are mandatory. The use of antiproteinuric drugs, such as anti-ACE inhibitors (ACEis) and hydroxyurea, should be considered in early stages. Here, we report a case of a female adolescent with SCD and inaugural nephrotic syndrome who, after an initial treatment failure with corticotherapy, had a remarkable recovery after treatment with hydroxyurea and ACEis.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Influence of hydroxyurea on the severity of acute chest syndrome in patients with sickle cell disease
    Gonzalez-Perez, Carlos
    Gomez-Carpintero Garcia, Ana
    Cervera Bravo, Aurea
    ANALES DE PEDIATRIA, 2022, 97 (01): : 63 - +
  • [22] No Sickle Cells in Sickle Cell Disease: Possible Effect of Hydroxyurea
    Kim, Stanley
    BLOOD, 2024, 144 : 5330 - 5330
  • [23] Impact of renal function on hydroxyurea exposure in sickle-cell disease patients
    Pressiat, Claire
    Rakotoson, Marie-Georgine
    Habibi, Anoosha
    Barau, Caroline
    Arrouasse, Raphaele
    Galacteros, Frederic
    Stehle, Thomas
    Audard, Vincent
    Hulin, Anne
    Bartolucci, Pablo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (05) : 2274 - 2285
  • [24] Hydroxyurea and arginine therapy: Impact on nitric oxide production in sickle cell disease
    Morris, CR
    Vichinsky, EP
    van Warmerdam, J
    Machado, L
    Kepka-Lenhart, D
    Morris, SM
    Kuypers, FA
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (08) : 629 - 634
  • [25] Is hydroxyurea leukemogenic in children with sickle cell disease?
    de Montalembert, M
    Davies, SC
    BLOOD, 2001, 98 (09) : 2878 - 2879
  • [26] Hydroxyurea therapy for sickle cell disease in Britain
    Olujohungbe, A
    Cinkotai, KI
    Yardumian, A
    BRITISH MEDICAL JOURNAL, 1998, 316 (7146): : 1689 - 1689
  • [27] HYDROXYUREA FOR THE TREATMENT OF SICKLE-CELL DISEASE
    ELHAZMI, MAF
    WARSY, AS
    ALMOMEN, A
    HARAKATI, M
    ACTA HAEMATOLOGICA, 1992, 88 (04) : 170 - 174
  • [28] Hydroxyurea, sickle cell disease and renal transplantation
    Allen, A
    Scoble, J
    Snowden, S
    Hambley, H
    Bellingham, A
    NEPHRON, 1997, 75 (01): : 106 - 107
  • [29] Minimal doses of hydroxyurea for sickle cell disease
    Lima, CSP
    Arruda, VR
    Costa, FF
    Saad, STO
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1997, 30 (08) : 933 - 940
  • [30] INFLUENCE OF HYDROXYUREA ON PICA IN SICKLE CELL DISEASE
    Viswanathan, Kusum
    Lakkaraja, Madhavi
    Esharif, Dyadin
    Nulu, Lakshmi
    Peichev, Mario
    Eksambe, Padmavati
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 53 - 53